< back to News

Defining the best therapy for acute myeloid leukemia. This is the goal of IMPACT-AML, a project funded by the European Commission under the Horizon Europe “Mission Cancer” programme. It is focused on Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), a high-impact disease in which no standard of care exists, and where there is an urgent need for new evidence on possible therapies. The aim of IMPACT-AML is to create an innovative and comprehensive framework to help defining future standards of care and ultimately improve patient outcomes.

“In Europe, more than 22,000 people are suffering from Relapsed or Refractory Acute Myeloid Leukemia, with little to no probability to be cured completely. The IMPACT-AML project aims to change this data and re-shape the treatment landscape of this serious disease” – illustrated Giovanni Martinelli, Associate Professor at the Department of Medical and Surgical Sciences of the University of Bologna and Scientific Coordinator of the IMPACT-AML project, explains the consortium’s vision.

With its consortium of 17 partners across Europe, the IMPACT-AML project builds a pioneering research and implementation framework for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), bringing togetehre patients, clinicians, and researchers across Europe and beyond. At its core, the STREAM platform enables real-world evidence integration and supports pragmatic clinical trials, laying the foundation for future patient-centric treatments and advancing collaborative innovation in AML care.

“IMPACT – AML’s mission is to collect quality data; develop a prospective clinical trial to increase treatment options for pediatric patients with acute myeloid leukemia; promote faster and more effective access to investigational molecules for frail patients; and develop a new pragmatic, randomized study on the best treatment sequence, particularly second-line therapeutic approaches” – stated Oriana Nanni, Director of Biostatistics and Clinical Trials at the Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” and coordinator of the IMPACT-AML project.

IMPACT AML is lead by Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’ – IRST IRCCS di Meldola e Università di Bologna and supported by a European Research and Innovation Framework programme Horizon Europe with 6 million euros.  The IMPACT-AML consortium is committed to transforming the treatment landscape of R/R AML by developing an inclusive research framework that ensures no patient is left behind. Through data harmonization, biobanking standardization, and the first cutting-edge clinical trials, the partners aim to generate robust scientific evidence that will drive better and standardised therapies across the EU, ensuring equitable access to care for all AML patients.